JAKAVI was studied in the most comprehensive clinical trial program in myelofibrosis to date1,2
Primary endpoint: Proportion of patients achieving a ≥35% reduction in spleen volume from baseline at Week 24 (as measured by magnetic resonance imaging [MRI] or computed tomography [CT] scan).
- Duration of maintenance of a ≥35% reduction from baseline in spleen volume
- Proportion of patients who had ≥50% reduction from baseline at Week 24 in TSS as measured by the modified MFSAF diary, version 2.0
- Change from baseline to Week 24 in TSS as measured by the modified MFSAF diary, version 2.0
- Overall survival